资讯

US FDA approves Verastem's ovarian cancer therapy
The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...
US FDA approves Verastem's cancer therapy
The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer ...
Reuters7 天
US FDA approves Verastem's ovarian cancer therapy
May 8 (Reuters) - The U.S. Food and Drug Administration has approved Verastem's (VSTM.O), opens new tab combination therapy for patients with a rare type of ovarian cancer who have received prior ...
Pharmabiz5 天
US FDA approves Verastem’s Avmapki Fakzynja combo therapy to treat patients with KRAS ...
US FDA approves Verastem’s Avmapki Fakzynja combo therapy to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer: Boston Saturday, May 10, 2025, 13:00 Hrs ...
STAT6 天
FDA approves Verastem’s ovarian cancer treatment
Matthew Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health ...
PMLive3 天
FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type
The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...
Fierce Pharma6 天
Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ...
In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...
PharmExec5 天
FDA Grants Accelerated Approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack for KRAS ...
The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...
Benzinga.com6 天
FDA approves Verastem's ovarian cancer treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the FDA’s new artificial intelligence effort in ...
The Pharma Letter6 天
FDA nod for first-ever treatment for LGSOC, a rare cancer
The US Food and Drug Administration (FDA) has approved Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) ...
Endpoints News6 天
FDA grants Ve­rastem first ap­proval for rare ovar­i­an can­cer treat­ment
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...
Cancer Therapy Advisor12 小时
Avmapki Plus Fakzynja Granted Accelerated Approval for Ovarian Cancer
The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.